Drug intelligence / Profile preview

punicalin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Punicalin is a natural ellagitannin found in pomegranate (*Punica granatum*) and is a structural derivative of punicalagin, specifically lacking the hexahydroxy-diphenic acid (HHDP) moiety. It functions as a selective inhibitor of **Protein Disulfide Isomerase Family A Member 3 (PDIA3)**, also known as ERp57, which is a chaperone protein primarily located in the endoplasmic reticulum involved in protein folding and disulfide bond formation. Research indicates that punicalin exhibits higher selectivity for PDIA3 over PDIA1 compared to punicalagin. By binding to PDIA3, punicalin induces thermal destabilization of the protein, leading to the formation and accumulation of intracellular protein aggregates. This mechanism makes it a compound of interest for the treatment of pathologies where PDIA3 is overexpressed or implicated, such as glioblastoma, inflammatory conditions, and neurodegenerative diseases.

Other names
4,6-gallagylglucose4,6-O-gallagyl-D-glucose
02

Targets

P4HB (Protein disulfide-isomerase)PDIA3 (Membrane-associated rapid response steroid-binding receptor)

Beyond the preview

Go deeper on punicalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on punicalin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call